NCT00188084Unknown不适用
Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial
University Hospital, Angers1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2003年11月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 400
- 试验地点
- 1
研究概览
简要总结
Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients:
- A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
- The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis.
The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival.
Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Defined Population
- 时间视角
- Prospective
入排标准
- 年龄范围
- 15 Years 至 59 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All GRAALL 2003 and 2005 enrolled patients with available frozen blast cells
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic LeukemiaNCT00482352Children's Oncology Group11,196
已完成
不适用
Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid LeukemiaAcute Myeloid LeukemiaSepsisNCT00806325Ohio State University120
Unknown
不适用
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AMLRisk-directed TherapyCytogenetic AbnormalityMolecular AbnormalityMRDNCT03620955Nanfang Hospital, Southern Medical University1,000
已完成
4 期
Treatment of High Risk Adult Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT00853008PETHEMA Foundation100
Unknown
不适用
New Markers for Minimal Residual Disease in Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT03249636Assiut University50
